Last Updated: November 5, 2026

Details for Patent: 9,090,558

Name: Drug Patent Intelligence for US Patent 9090558
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,090,558 protect, and when does it expire?

Patent 9,090,558 protects VUMERITY and is included in one NDA.

This patent has sixty-one patent family members in thirty-one countries.

Summary for Patent: 9,090,558

Title:	Prodrugs of fumarates and their use in treating various diseases
Abstract:	The present invention provides compounds of formula (I), wherein: The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.
Inventor(s):	Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
Assignee:	Alkermes Pharma Ireland Ltd
Application Number:	US14/180,687
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,090,558
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,090,558

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen	VUMERITY	diroximel fumarate	CAPSULE, DELAYED RELEASE;ORAL	211855-001	Oct 29, 2019	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING MULTIPLE SCLEROSIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,090,558

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2970101	⤷ Start Trial	301165	Netherlands	⤷ Start Trial
European Patent Office	2970101	⤷ Start Trial	PA2022003	Lithuania	⤷ Start Trial
European Patent Office	2970101	⤷ Start Trial	2022C/507	Belgium	⤷ Start Trial
European Patent Office	2970101	⤷ Start Trial	LUC00251	Luxembourg	⤷ Start Trial
European Patent Office	2970101	⤷ Start Trial	CA 2022 00010	Denmark	⤷ Start Trial
European Patent Office	2970101	⤷ Start Trial	122022000014	Germany	⤷ Start Trial
European Patent Office	2970101	⤷ Start Trial	8/2022	Austria	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.